

Contents

1 Metabolism and Roles of Eicosanoids in Brain.....	1
1.1 Introduction.....	1
1.2 Multiplicity of Cyclooxygenases, Lipoxygenases, and Epoxygenases in the Brain	4
1.2.1 Cyclooxygenases (COXs)	6
1.2.2 Lipoxygenases (LOXs)	11
1.2.3 Cytochrome P450 Epoxygenases (EPOXs)	13
1.3 Eicosanoids and Their Receptors in Brain.....	15
1.4 Interplay Among COX, LOX, and EPOX-derived Products, and Relationship to Upstream PLA ₂ Isoforms	22
1.5 Roles of Eicosanoids in the Brain.....	25
1.5.1 Eicosanoids in Neuroinflammation.....	25
1.5.2 Eicosanoids in Neurodegeneration.....	27
1.5.3 Eicosanoids in Nociception (Pain State).....	28
1.5.4 Eicosanoids in Synaptic Plasticity	28
1.6 Eicosanoids in Neurotraumatic Diseases.....	29
1.6.1 Eicosanoids in Ischemic Injury	30
1.6.2 Eicosanoids in Spinal Cord Trauma.....	31
1.6.3 Eicosanoids in Traumatic Brain Injury	31
1.6.4 Eicosanoids in Epilepsy	32
1.7 Eicosanoids in Neurodegenerative Diseases.....	32
1.7.1 COX, LOX, EPOX, and Eicosanoids in AD.....	33
1.7.2 COX, LOX, EPOX, and Eicosanoids in PD.....	35
1.7.3 COX, LOX, EPOX, and Eicosanoids in Amyotrophic Lateral Sclerosis.....	35
1.7.4 COX, LOX, EPOX, and Eicosanoids in Creutzfeldt-Jakob Disease (CJD).....	36
1.8 Conclusions.....	37
References.....	37

2	Recent Development on the Neurochemistry of Docosanoids.....	49
2.1	Introduction.....	49
2.2	Importance of n-3 Polyunsaturated Fatty Acids in the Brain.....	50
2.3	EPA-Derived Lipid Mediators in the Brain.....	52
2.4	DHA-Derived Lipid Mediators in the Brain.....	58
2.4.1	17S D Series Resolvins.....	60
2.4.2	Protectins and Neuroprotectin.....	60
2.5	Conclusion.....	68
	References.....	68
3	Metabolism, Roles, and Involvement of Lyso-glycerophospholipids in Neurological Disorders.....	73
3.1	Introduction.....	73
3.2	Deacylation/Reacylation Cycle (Land's Cycle) and Its Importance.....	74
3.2.1	Acyl-CoA Synthetases in the Brain.....	75
3.2.2	Acyl-CoA: Lyso-phospholipid Acyltransferase in the Brain.....	77
3.2.3	Phospholipases A ₂ (PLA ₂) in the Brain.....	78
3.2.4	Long-Chain Acyl-CoA Hydrolase or Thioesterases in the Brain.....	80
3.2.5	CoA-independent Reacylation in the Brain.....	81
3.3	Effects of Lysophospholipids on Neural Membrane Metabolism.....	82
3.3.1	Lysophosphatidylcholine (Lyso-PtdCho).....	82
3.3.2	Lyso-phosphatidylethanolamine (Lyso-PtdEtn).....	85
3.3.3	Lyso-phosphatidylserine (Lyso-PtdSer).....	86
3.3.4	Lyso-phosphatidylinositol (Lyso-PtdIns).....	87
3.3.5	Lyso-cardiolipin (Lyso-Ptd ₂ Gro).....	88
3.3.6	Lyso-ethanolamine and Choline Plasmalogens (Lyso-PlsEtn and Lyso-PlsCho).....	89
3.3.7	Lyso-phosphatidic Acid (Lyso-PtdH).....	90
3.4	Lyso-phospholipids in Neurotraumatic and Neurodegenerative Diseases.....	93
3.4.1	Lyso-phospholipids in Ischemic Injury.....	94
3.4.2	Lyso-phospholipids in Alzheimer Disease.....	95
3.4.3	Lyso-phospholipids in MS and EAE.....	96
3.4.4	Lyso-phospholipids in NCL.....	97
3.5	Conclusion.....	97
	References.....	97

4 Platelet-Activating Factor in Brain: Its Metabolism, Roles, and Involvement in Neurological Disorders	107
4.1 Introduction.....	107
4.2 PAF Biosynthesis in the Brain	108
4.2.1 <i>De Novo</i> Synthesis of PAF.....	109
4.2.2 Remodeling Pathway for PAF Synthesis	111
4.2.3 Oxidative Fragmentation Pathway for PAF Synthesis	114
4.3 Catabolism of PAF in the Brain	114
4.4 PAF Receptors in the Brain.....	116
4.5 PAF in Neurological and Visceral Disorders	118
4.5.1 PAF in Neurological Disorders	118
4.5.2 PAF in Visceral Disorders	123
4.5.3 PAF in Kainic Acid Neurotoxicity	124
4.6 Molecular Mechanism Associated with PAF-Mediated Neural Injury	124
4.7 Conclusion	125
References.....	126
 5 Cannabinoids in the Brain: Their Metabolism, Roles, and Involvement in Neurological Disorders	 133
5.1 Introduction.....	133
5.2 Cannabinoid Receptor-Mediated Signaling in the Brain	136
5.3 Occurrence and Synthesis of Endocannabinoids in the Brain	137
5.3.1 Metabolism of 2-Arachidonylglycerol in the Brain	139
5.3.2 Metabolism of Anandamide in the Brain.....	142
5.4 Interplay Among Cannabinoid, Glutamate, and Dopamine Receptors in the Basal Ganglia.....	143
5.5 Endocannabinoids and Neurological Disorders.....	144
5.5.1 Endocannabinoids in Neurotraumatic Diseases	145
5.5.2 Endocannabinoids in Neurodegenerative Disorders	147
5.6 Use of FAAH and MGL Inhibitors for Inflammatory Pain.....	149
5.7 Conclusion	150
References.....	151
 6 Neurochemical Aspects of 4-Hydroxynonenal	 159
6.1 Introduction.....	159
6.2 Synthesis of 4-HNE in the Brain	160
6.3 Metabolism of 4-HNE in the Brain.....	161
6.4 Effect of 4-HNE on Enzyme Activities	163
6.4.1 Modulation of Kinases by 4-HNE	164
6.4.2 Modulation of Caspases by 4-HNE	166
6.4.3 Modulation of Glutathione S-Transferases by 4-HNE	167

6.4.4	Modulation of ATPases by 4-HNE.....	169
6.4.5	Modulation of Other Enzymes and Cell Cycle by 4-HNE.....	170
6.4.6	Modulation of Heat Shock Response by 4-HNE.....	170
6.5	Modulation of NMDA Receptor by 4-HNE	171
6.6	Modulation of Gene Expression by 4-HNE.....	172
6.7	Modulation of Peroxisomes by 4-HNE.....	173
6.8	Modulation of Nucleic Acid Metabolism by 4-HNE.....	173
6.9	Modulation of Phospholipid Metabolism by 4-HNE.....	175
6.10	Modulation of Blood–Brain Barrier by 4-HNE.....	175
6.11	4-HNE in Neurological Disorders	176
6.11.1	4-HNE in Alzheimer Diseases.....	176
6.11.2	4-HNE in Parkinson Disease	177
6.11.3	4-HNE in Amyotrophic Lateral Sclerosis	178
6.11.4	4-HNE in Prion Diseases.....	179
6.11.5	4-HNE in Ischemia	179
6.11.6	4-HNE in Spinal Cord Injury	180
6.11.7	4-HNE in Traumatic Brain Injury.....	181
6.11.8	4-HNE in Kainic Acid Neurotoxicity.....	183
6.12	4-Hydroxyhexenal (4-HHE)	183
6.13	Conclusion	184
	References.....	184
7	Isoprostanes and Other Nonenzymic Polyunsaturated Fatty Acid-Derived Lipid Mediators in the Brain	193
7.1	Introduction.....	193
7.2	Generation of IsoPs in the Brain.....	194
7.3	Degradation of IsoPs in the Brain.....	195
7.4	IsoPs and Signal Transduction Processes	198
7.5	IsoPs in Neurodegenerative Diseases.....	202
7.6	IsoPs in Neurotraumatic Diseases.....	204
7.7	NPs in Neurological Disorders	204
7.8	Isoketals (Isolevuglandins) in Neurological Disorders.....	206
7.9	Neuroketals in Neurological Disorders.....	207
7.10	Isofurans in Neurological Disorders	208
7.11	Neurofurans in Neurological Disorders	209
7.12	IsoPs in Kainic Acid Neurotoxicity	209
7.13	Conclusion	210
	References.....	211
8	Ceramide and Ceramide 1 Phosphate in the Brain	217
8.1	Introduction.....	217
8.2	Synthesis of Ceramide and Ceramide 1-phosphate in the Brain.....	221
8.3	Degradation of Ceramide and Ceramide 1-phosphate in the Brain.....	227

8.4	Roles of Ceramide and Ceramide 1-phosphate in the Brain.....	228
8.5	Ceramide in Neurological Disorders.....	229
8.5.1	Ceramide in Ischemic Injury	231
8.5.2	Ceramide in Alzheimer Disease	232
8.5.3	Ceramide in Parkinson Disease	234
8.5.4	Ceramide in Amyotrophic Lateral Sclerosis	234
8.5.5	Ceramide in Multiple Sclerosis	235
8.5.6	Ceramide in HIV-1	235
8.5.7	Ceramide in Batten Disease.....	236
8.5.8	Ceramide in Major Depressive Disorders.....	236
8.5.9	Ceramide in Kainic Acid Neurotoxicity.....	236
8.6	Conclusion.....	237
	References.....	238
9	Sphingosine and Sphingosine 1 Phosphate in the Brain.....	245
9.1	Introduction	245
9.2	Sphingosine Kinases in the Brain	248
9.3	Sphingosine 1 Phosphate Receptors in the Brain.....	251
9.4	Sphingosylphosphorylcholine in the Brain	254
9.5	FTY720 and Its Neurochemical Effects.....	255
9.6	Sphingosine 1 Phosphate in Neurological Disorders.....	257
9.6.1	Sphingosine 1 Phosphate in Ischemia	257
9.6.2	Sphingosine 1 Phosphate in Traumatic Brain and Spinal Cord Injuries	259
9.6.3	Sphingosine 1 Phosphate in Alzheimer Disease	259
9.6.4	Sphingosine 1 Phosphate in Multiple Sclerosis.....	260
9.6.5	Sphingosine 1 Phosphate in Kainic Acid Neurotoxicity	261
9.7	Conclusion.....	261
	References.....	262
10	Cholesterol and Hydroxycholesterol in the Brain.....	267
10.1	Introduction.....	267
10.2	Synthesis of Cholesterol and Hydroxycholesterols in the Brain	269
10.3	Degradation of Cholesterol in the Brain	275
10.4	Roles of Hydroxycholesterols in the Brain.....	277
10.4.1	Hydroxycholesterols in Neural Cell Differentiation	278
10.4.2	Hydroxycholesterols in Exocytosis	279
10.4.3	Hydroxycholesterols in Apoptosis	279
10.5	Cholesterol and Hydroxycholesterols in Neurological Disorders	281
10.5.1	Cholesterol and Hydroxycholesterol in Alzheimer Disease.....	282
10.5.2	Cholesterol and Hydroxycholesterol in Parkinson Disease.....	284

10.5.3	Cholesterol and Hydroxycholesterol in Huntington Disease.....	285
10.5.4	Cholesterol and Hydroxycholesterols in Niemann-Pick Type C.....	286
10.5.5	Cholesterol and Hydroxycholesterol in Multiple Sclerosis.....	287
10.5.6	Hydroxycholesterol in Traumatic Brain Injury	288
10.5.7	Cholesterol and Hydroxycholesterols in Cerebrotendinous Xanthomatosis.....	288
10.6	Cholesterol and Hydroxycholesterols in Kainic Acid Neurotoxicity	289
10.7	Conclusion	290
	References.....	291
11	Perspective and Direction for Future Studies on Lipid Mediators	299
11.1	Introduction.....	299
11.2	Lipid Mediators in the Brain.....	300
11.3	Interactions Among Phospholipid-, Sphingolipid-, and Cholesterol-Derived Lipid Mediators in the Brain.....	303
11.4	Detection and Levels of Lipid Mediators in Neurological Disorders by Lipidomics	306
11.5	Modulation of Lipid Mediators by Diet.....	308
11.6	Conclusion	309
	References.....	310
	Index.....	315



<http://www.springer.com/978-1-4419-9939-9>

Lipid Mediators and Their Metabolism in the Brain

Farooqui, A.A.

2011, XXIV, 327 p., Hardcover

ISBN: 978-1-4419-9939-9